Search Results

Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study.

Vedanta Biosciences announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024.

PureTech Health plc noted that its Founded Entity, Vedanta Biosciences announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection.

Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.

Vedanta Biosciences today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.

Vedanta Biosciences today announced that management will host investor meetings at the Wells Fargo Virtual Private Biotech Symposium being held on Wednesday, November 1, 2023.

Vedanta Biosciences today announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 was dosed.

Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).